Point Therapeutics to Present at the Pacific Growth Equities Life Sciences Growth Conference
June 07 2006 - 7:22AM
Business Wire
Point Therapeutics, Inc. (NASDAQ:POTP) announced that Don Kiepert,
President and CEO, will present at the Pacific Growth Equities Life
Sciences Growth Conference at the InterContinental Mark Hopkins
Hotel in San Francisco on Tuesday, June 13, 2006 at 9:00 a.m.
Pacific Time/12:00 p.m. Eastern Time. Mr. Kiepert will review key
research and development accomplishments and discuss upcoming
corporate initiatives. A live Web cast of the presentation will be
available on the Company's Web site, www.pther.com. About Point
Therapeutics, Inc.: Point is a Boston-based biopharmaceutical
company developing a portfolio of dipeptidyl peptidase (DPP)
inhibitors for use in cancer, type 2 diabetes and as vaccine
adjuvants. Point is currently studying its lead product candidate,
talabostat, in two Phase 3 trials in non-small cell lung cancer.
Point is also studying talabostat in several Phase 2 trials,
including as a single-agent in metastatic melanoma, in combination
with cisplatin in metastatic melanoma, in combination with
rituximab in advanced chronic lymphocytic leukemia, and in
combination with gemcitabine in metastatic pancreatic cancer. In
addition, Point's portfolio includes two other DPP inhibitors in
preclinical development--PT-630 for type 2 diabetes, and PT-510 as
a vaccine adjuvant.
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Point Therapeutics (MM) (NASDAQ): 0 recent articles
More Point Therapeutics, Inc. News Articles